Hadassah

Galmed Pharma Names Hadassah’s Dr. Ran Oren as Chief Medical Officer

Friday, Aug 5 2016

Chief Medical Officer Dr. Ran Oren.

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of liver diseases, has named Prof. Ran Oren, head of the Hadassah Medical Organization’s Institute of Gastroenterology and Liver Disease, as its new Chief Medical Officer.

Having received his medical degree from the Hadassah-Hebrew University School of Medicine, as well as residency training in internal medicine, gastroenterology, and liver pathology at Hadassah, Prof. Oren also completed a fellowship in New York City, combining research at Albert Einstein College of Medicine and advanced clinical fellowship at the Liver Division of Mount Sinai Medical Center. In 2000, Dr. Oren established the Liver Unit at the Tel Aviv Sourasky Medical Center, where he also served as Chief of Medicine from 2008 to 2010. Dr. Oren concurrently served as the President of the Israeli Association for the Study of the Liver between 2007 and 2010.  In 2010, he became head of Hadassah’s Institute of Gastroenterology and Liver Disease.

A scientific collaborator of the late Prof. Tuvia Gilat, Co-founder of Galmed, Prof. Oren has served as a member of Galmed’s Scientific Advisory Board since 2014. Prof. Oren was the principal investigator of Aramchol's Phase IIa study, reports Allen Baharaff, Galmed's President and Chief Executive Officer, “and we are privileged that he has agreed to join Galmed and lead the clinical development of Aramchol."

Prof. Oren notes: "I am honored to continue the life work of Prof. Gilat, who was my mentor and friend for many years. I have been scientifically and clinically involved in the field of NAFLD (non-alcoholic fatty liver disease) since the early 2000’s. I view this position at Galmed as an exciting opportunity for me to contribute to a company that I have been following from concept to this exciting phase of advanced clinical studies, and I look forward to working with the Galmed team."

Comments

No comments yet.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Wednesday, Nov 30 2016

Hadassah Teams Up with Spinal Cord Institute to Study Outcomes of Traumatic Injuries

The medical interventions and outcomes for Israelis with a spinal cord injury (SCI) will now be captured in the Rick Hansen SCI Registry (RHSCIR), thanks to the November 16th launch of a partnership between the Hadassah Medical Organization and the Rick Hansen Institute (RHI), a Canadian-based not-for-profit organization named after the paralympic athlete who suffered a severe spinal cord injury following a car accident.

READ MORE ›
alt_text

Thursday, Nov 17 2016

A Birthday Party in Hadassah’s PICU: Helping a Four-Year-Old Recover

Yehoshua "Shuki" Pepper was crossing a Jerusalem street with an older sibling when a car ran him over. He was rushed to Hadassah Hospital Ein Kerem's Pediatric Intensive Care Unit in fair condition, but he wasn't speaking and subsequent MRIs of his head injury were worrisome.

READ MORE ›
alt_text

Thursday, Nov 17 2016

Ethiopian Pre-Nursing Students: On the Way to Fulfilling a Dream

“I know that some people are fine with looking at a screen all day, but I know I need the human touch--to work with people. I want to be a nurse, " relates Sarah Talala, one of the 18 students of Ethiopian background who were given the opportunity to take a course which enabled them to advance to pre-academic studies at the Hebrew University and then on to nursing school at the Hadassah-Hebrew University Henrietta Szold School of Nursing.

READ MORE ›
alt_text

Monday, Nov 14 2016

Granalix BioTechnologies Introduces Food Additive to Protect Against Neurodegenerative Disease

Granalix BioTechnologies, whose founder and Chief Executive Officer is Hadassah Medical Organization Experimental Neurologist Prof. Ruth Gabizon, has launched a food supplement containing pomegranate oil that has proven to protect against neurodegenerative diseases in pre-clinical models.

READ MORE ›

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Membership Questions

membership@hadassah.org

(800) 664-5646

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Missions Department

missions@hadassah.org

(800) 237-1517

Show More